EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

An Inhibitory Aptamer Against PDGF-C Overcomes Anti-VEGF Refractoriness and Reduces Choroidal Neovascularization and Fibrosis

Rongyuan Chen, Weiwei Lu, Juanhua Zhu, Lijuan Huang, Wei Chen, Guanqun Huang, Xiangrong Ren, Qihang Sun, Jiaxin Hu, Jiani Li, Shasha Wang, Haiqing Kuang and 17 more

Investigative Ophthalmology & Visual Science · 2026

DOI: 10.1167/iovs.67.5.36 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Rongyuan Chen and 28 co-authors. Institution: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University and Guangdong Provincial Key Laboratory of Ophthalmology a…. Major MEDLINE topics: Choroidal Neovascularization, Platelet-Derived Growth Factor, Aptamers, Nucleotide, Lymphokines. 102 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

Wet age-related macular degeneration is a leading cause of irreversible vision loss, primarily due to choroidal neovascularization (CNV) and subsequent fibrosis. Although current anti-vascular endothelial growth factor A (anti-VEGF) therapies offer significant benefits, many patients exhibit limited or no response and develop drug resistance over time, necessitating the exploration of complementary or alternative therapeutics. This study aimed to identify and characterize a platelet-derived growth factor-C (PDGF-C)-targeting DNA aptamer and to evaluate its therapeutic potential for suppressing CNV and fibrosis, including in an anti-VEGF-refractory setting.

Methods

A DNA aptamer against PDGF-C (α-PC aptamer) was identified using systematic evolution of ligands by exponential enrichment. Its binding to PDGF-C and inhibition of PDGF-C/platelet-derived growth factor receptor alpha (PDGFRα) interaction were assessed using surface plasmon resonance. The effects of the α-PC aptamer on PDGF-C-induced proliferation, migration, and PDGFRα, Akt, and extracellular-regulated kinase (ERK) signaling were examined in fibroblasts and human umbilical vein smooth muscle cells (HUVSMCs). In vivo efficacy was evaluated in a laser-induced CNV mouse model, including anti-VEGF refractory aged mice.

Results

The α-PC aptamer specifically bound to PDGF-C and effectively blocked its binding to PDGFRα. The α-PC aptamer significantly inhibited PDGFRα, Akt, and ERK activation and suppressed PDGF-C-induced proliferation and migration of both fibroblasts and HUVSMCs. Importantly, in a laser-induced CNV mouse model, the α-PC aptamer markedly reduced neovascularization and fibrosis; it particularly retained efficacy in suppressing CNV in anti-VEGF refractory aged mice, where anti-VEGF treatment failed to do so.

Conclusions

These findings suggest that the α-PC aptamer represents a promising therapeutic agent for treating neovascular diseases, especially in patients refractory to anti-VEGF treatment.

Subjects

MeSH terms (MEDLINE)

Choroidal NeovascularizationPlatelet-Derived Growth FactorAptamers, NucleotideLymphokinesVascular Endothelial Growth Factor AAnimalsFibrosisMiceHumansDisease Models, AnimalAngiogenesis InhibitorsCell ProliferationMice, Inbred C57BLCell MovementCells, CulturedSurface Plasmon ResonanceReceptor, Platelet-Derived Growth Factor alpha

Substances

Platelet-Derived Growth FactorAptamers, Nucleotideplatelet-derived growth factor CLymphokinesVascular Endothelial Growth Factor AAngiogenesis InhibitorsReceptor, Platelet-Derived Growth Factor alpha

Authors and institutions

  • State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University and Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
  • Department of Ophthalmology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
  • Physical Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Genetic Diseases Key Laboratory of Sichuan Province, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, Univ…
  • Affiliated Eye Hospital of Nanjing Medical University, Nanjing, China.
  • Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.

Cite

APA

Chen, R., Lu, W., Zhu, J., Huang, L., Chen, W., Huang, G., Ren, X., Sun, Q., Hu, J., Li, J., Wang, S., Kuang, H., Lee, C., Lu, W., Xiong, Z., Liu, Y., Wang, X., Prodeus, A., Zhu, X., …, & Li, X. (2026). An Inhibitory Aptamer Against PDGF-C Overcomes Anti-VEGF Refractoriness and Reduces Choroidal Neovascularization and Fibrosis. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.5.36

Vancouver

Chen R, Lu W, Zhu J, Huang L, Chen W, Huang G, et al. An Inhibitory Aptamer Against PDGF-C Overcomes Anti-VEGF Refractoriness and Reduces Choroidal Neovascularization and Fibrosis. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.5.36

BibTeX
@article{Chen2026,
  author = {Chen, Rongyuan and Lu, Weiwei and Zhu, Juanhua and Huang, Lijuan and Chen, Wei and Huang, Guanqun and Ren, Xiangrong and Sun, Qihang and Hu, Jiaxin and Li, Jiani and Wang, Shasha and Kuang, Haiqing and Lee, Chunsik and Lu, Weisi and Xiong, Zhen and Liu, Yi and Wang, Xiaolu and Prodeus, Aaron and Zhu, Xianjun and Zhang, Qiuyang and Li, Keran and Deng, Aijun and Cao, Yihai and Yao, Yong and Gariepy, Jean and Liu, Xialin and Yang, Zhenglin and Jiang, Qin and Li, Xuri},
  title = {An Inhibitory Aptamer Against PDGF-C Overcomes Anti-VEGF Refractoriness and Reduces Choroidal Neovascularization and Fibrosis},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2026},
  doi = {10.1167/iovs.67.5.36}
}
Start for free →